Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Revenue of Tiziana Life Sciences Ltd (TLSA)
Revenue in 2022 (TTM): $
According to Tiziana Life Sciences Ltd's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tiziana Life Sciences Ltd
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $-51,000 | $-15,339,000 | $-15,397,000 | $-16,208,000 |
| 2021 | $ | $-141,000 | $-26,340,000 | $-26,657,000 | $-23,417,000 |
| 2020 | $ | $-89,764 | $-32,168,118 | $-30,073,456 | $-27,730,760 |
| 2019 | $ | $-250,044 | $-9,933,393 | $-10,287,408 | $-9,579,378 |
| 2018 | $ | $ | $-9,431,784 | $-9,458,431 | $-7,607,096 |
| 2017 | $ | $ | $-11,128,830 | $-11,155,858 | $-9,149,020 |
| 2016 | $ | $ | $-8,982,110 | $-9,003,085 | $-8,893,276 |
| 2015 | $ | $ | $-12,761,671 | $-12,788,338 | $-12,788,338 |
| 2014 | $ | $ | $-4,017,246 | $-5,556,593 | $-5,463,205 |
| 2013 | $3 K | $3 K | $-476,560 | $-466,666 | $-466,666 |
| 2012 | $ | $ | $-425,009 | $-1,055,251 | $-1,055,251 |
| 2011 | $-127,313 | $-127,313 | $-448,702 | $-448,702 | $-1,207,924 |
| 2010 | $ | $ | $-3,031,000 | $ | $-4,678,047 |
| 2009 | $90.55 K | $72.77 K | $-832,754 | $-1,225,684 | $-1,180,408 |
| 2008 | $134.73 K | $103.97 K | $-1,767,540 | $-2,211,255 | $-2,142,428 |
| 2007 | $126.92 K | $79.33 K | $-5,001,487 | $-5,128,409 | $-4,729,797 |
| 2006 | $793.48 K | $384.01 K | $-4,218,178 | $-4,494,426 | $-4,263,239 |
| 2005 | $199.6 K | $130.77 K | $-3,751,118 | $-3,825,108 | $-3,684,011 |
| 2004 | $189.89 K | $103.58 K | $-2,832,975 | $-2,880,927 | $-2,662,268 |
| 2003 | $ | $ | $-2,125,000 | $-3,557,143 | $-3,503,571 |
| 2002 | $ | $ | $-2,939,518 | $-3,818,958 | $-3,715,873 |
| 2001 | $ | $ | $-3,365,154 | $-3,507,548 | $-3,378,231 |
| 2000 | $ | $ | $-3,487,573 | $-3,511,471 | $-3,387,501 |
| 1999 | $ | $ | $-668,112 | $-896,208 | $-896,208 |
| 1998 | $ | $ | $-205,826 | $-451,490 | $-451,490 |